title: Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH.
abstract: REACH requires health risk management for workers and the general population and introduced the concept of Derived No-Effect Level (DNEL). DNELs must be derived for all substances that are classified as hazardous. In analogy to other health-risk based guidance values, such as reference doses (RfDs) and tolerable daily intakes (TDIs), risk to health is considered negligible if the actual exposure is less than the DNEL. Exposure assessment is relatively simple for occupational situations but more complex for the general public, in which exposure may occur via multiple pathways, routes, and media. For such complex or partially defined exposure scenarios, human biomonitoring (HBM) gives a snapshot of the internal or absorbed dose of a chemical and is often the most reliable exposure assessment methodology. For human risk management, HBM data can be interpreted using the recently developed concept of Biomonitoring Equivalents (BEs). Basically, a BE translates an established reference value into a biomarker concentration using toxicokinetic data. If the results of an exposure assessment using HBM indicate that the levels measured are below the DNEL-based BE (BE(DNEL)), it would indicate that the combined exposure via all potential exposure routes is unlikely to pose a risk to human health and that health risk management measures might not be needed. Hence, BEs do not challenge existing risk assessments but rather build upon them to help risk management, the ultimate goal of any risk assessment. A challenge in implementing this approach forms the limited availability of toxicokinetic information for many substances. However, methodologies such as generic physiologically based toxicokinetic models, which allow estimation of biomarker concentrations based on physicochemical properties, are being developed for less data-rich chemicals. Acceptance of the use of BE by regulatory authorities will allow initial screening of population exposure to chemicals to identify those chemicals requiring more detailed risk and exposure assessment, assisting in priority setting and ultimately leading to improved product stewardship and risk management.
authors.affiliation: Shell International BV, Shell Health, PO Box 162, 2501 AN The Hague, The Netherlands. peter.boogaard@shell.com
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Boogaard
authors.forename: Lesa L
authors.initials: LL
authors.lastname: Aylward
authors.forename: Sean M
authors.initials: SM
authors.lastname: Hays
mesh_terms: D015415:Biomarkers / Q000032:analysis; D004781:Environmental Exposure / Q000032:analysis; D004784:Environmental Monitoring / Q000379:methods; D005062:European Union; D006207:Half-Life; D015386:Hazardous Substances / Q000032:analysis; D006801:Humans; D019055:No-Observed-Adverse-Effect Level; D012016:Reference Values; D018570:Risk Assessment / Q000379:methods*
chemical_list: D015415:Biomarkers; D015386:Hazardous Substances